Business Wire

ALTER-DOMUS

19.7.2022 09:02:07 CEST | Business Wire | Press release

Share
Leading Fund Administrator Alter Domus Appoints Gus Harris to its Group Executive Board

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has appointed Gus Harris, Head of AD Data & Analytics, to its Group Executive Board (GEB) where he will continue to report to Doug Hart, Chief Executive Officer.

In his current role, Gus leads Alter Domus’ data and analytics products strategy and team, developing new data assets and offerings to provide value-add solutions to alternatives market participants, including risk managers, investment managers, analysts and support functions at investor and asset manager clients. The team will help clients bring their data into a modern technology-enabled environment, allowing them to develop a competitive edge in their ability to efficiently generate meaningful and timely insights from their most crucial data sets.

As an extension to our data and analytics efforts, Gus is overseeing the development of proprietary applications into Software-as-a-Service (SaaS) products, which will further expand Alter Domus’ reach into the middle and front offices of their expanding client base. Early product development has focused on solutions which improve operational governance and efficiency for clients to more effectively risk-manage, monitor and grow their alternatives portfolios. The team has lined up several clients, including new clients, and strategic partnerships to accelerate their go-to-market and will have several newly built products by year-end.

Since joining Alter Domus last October, Gus has hired a world-class team to oversee the firm’s growth in this important area. The seasoned team, which has extensive experience building similar solutions for large financial institutions globally, brings together significant capabilities around modern big data, data science, technology, and product management disciplines. Team members have honed their skills at, and joined Alter Domus directly from, reputable institutions such as Amazon Web Services, Morgan Stanley, Moody’s Analytics, KPMG, and other established multinational organizations.

“Technology has been an integral part of the backbone of Alter Domus’ offering to clients, and Gus has brought an innovative and forward-thinking vision to our data and analytics services. Clients are under increasing pressure to better manage and exploit data, which makes Gus’ voice and perspective at a group executive level particularly important,” said Doug Hart . “Gus brings a strong sense of leadership, collegiality, and considerable expertise to our leadership team, key traits which have helped to catalyze his team’s growth and offering in a relatively short period of time.”

“I am proud to join Alter Domus’ group executive board, and I look forward to partnering with this talented and dynamic group of executive leaders. Alter Domus’ data and analytics team, which is comprised of seasoned and proven industry professionals, is undergoing tremendous growth and is already engaging with leading general and limited partners in the private equity, private debt – including CLO managers and investors – and commercial real estate sectors on complex and important projects,” said Gus Harris . “This reflects the increasingly important role that data and analytics will play in the future of our business, and the alternative investment industry as a whole. As the marketplace matures, demand for ‘better data’ will only continue to grow, and we are extremely well-positioned to support the market on this transformational journey. With technology running across the spectrum of our data solutions – from collection, to analytics, to delivery – we’re thrilled to be helping clients define the standards that will set their business on a solid foundation for sustainable future growth.”

Prior to joining Alter Domus in September 2021, Gus was a founding executive of Moody’s Analytics where he helped build several flagship products and services including Moody’s structured-finance products, ESG data and research services, Moody’s DataHub (DaaS), and other SaaS tools. Gus is a CPA and CFA charter holder and completed advanced degrees in finance from Columbia Business School, risk and statistics from New York University’s Stern School of Business, and technology from Pace University.

About Alter Domus

Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release

STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD

Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release

Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to

Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria

Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm

SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release

SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye